Blood Clotting Factors Market Size And Forecast to 2022

According to Precision Business Insights (PBI), the global blood clotting factors market size was valued at USD 3,178.2 billion in 2021 and is poised to grow at a significant CAGR of 6.9% during the forecast period 2022 to 2028. The global Blood Clotting Factors market is segmented into the following types: by Product Type (Factors VII, Factor VIII, Factor IX, Factor X, Factor XIII, Von Willebrand Factor, Anti-Inhibitor Coagulant Complex, and Others), By Application (Haemophilia, Von Willebrand Disease, Surgery, and Other Bleeding Disorders), By Technology (Plasma-derived and Recombinant), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) and Forecast to 2028. Key players' profiles in the Blood Clotting Factors market report are Angio Dynamics, Terumo Co., Johnson, and Johnson, ECKOS Co., Bayer HealthCare LLC, Boston Scientific Co., Argon Medical Devices, Medtronic Plc, Teleflex Incorporated, Penumbra. The rising number of traumas is fuelling the expansion of the blood coagulation factor market. Similarly, an increase in the number of accidents, as well as an increase in the diagnostic rate of blood clotting disorders, are driving the growth of the worldwide blood coagulation factor market. Yet, obstacles such as tight regulatory standards and a lack of plasma may stymie the global market for blood coagulation factors.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/blood-clotting-factors-market/

Factor VIII Segment to Dominate the Blood Clotting Factors Market
Amongst product types, the Factor VIII segment held a considerable market during the estimated period. One of the primary factors driving market expansion is the rising prevalence of haemophilia A due to clotting factor VIII deficiency. Haemophilia A is an X-linked recessive condition caused by a deficiency in functional plasma clotting factor VIII (FVIII). It can be inherited or arise spontaneously. The development of inhibitory alloantibodies to FVIII can greatly complicate genetic case treatment. FVIII autoantibodies are rarely the cause of acquired haemophilia A. According to the National Haemophilia Foundation, one in 10,000 persons are born with haemophilia A owing to clotting factor VIII insufficiency in 2018, and one in 50,000 are born with haemophilia B due to clotting factor IX deficiency in 2018. With the rising number of haemophilia, A patients, FDA medication approvals are likely to rise, driving the market expansion of this sector. For example, the Korean Ministry of Food and Drug Safety authorised CSL Behring's Afstyla, a novel preventive medication for haemophilia A developed in Korea, on January 26th, 2020. The medicine has been licensed by the Government to treat children and adults with haemophilia A.

Asia Pacific Blood Clotting Factors Market
The global epilepsy device market, based on region, is segmented into America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Due to the increasing number of welfare programs and the significant development of disposable money, Asia-Pacific is expected to be the fastest-expanding region in the market. Also, the growing number of people suffering from bleeding disorders drives the growth of the market in this area. Von Willebrand Disease (VWD), a hereditary bleeding illness, affects roughly 200,000 people in Australia each year, according to Haemophilia Foundation Australia figures.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players.

The global Blood Clotting Factors market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

In 19th February 2019, The FDA has accepted Novo Nordisk's ESPEROCT Biologics License Application for the treatment of adults and children with hemophilia A.

In June 2018, Octapharma reported in June 2018 that the European Medicines Agency (EMA) had accepted an extension of marketing authorisation for Nuwiq, a human cell line-derived recombinant factor VIII (rFVIII) for the treatment of haemophilia A patients.

Request sample report at- https://precisionbusinessinsights.com/request-sample/?product_id=65324

Detailed Segmentation
The Blood Clotting Factors market is segmented based on Product type, Application, Technology, Distribution Channel, and geography.

Based on the Product Type, the market is segmented into the following:
• Factor VII
• Factor VIII
• Factor IX
• Factor X
• Factor XIII
• Von Willebrand Factor
• Anti-Inhibitor Coagulant Complex
• Others

Based on the Application, the market is segmented into the following:
• Haemophilia
• Von Willebrand disease (VWD)
• Surgery
• Other bleeding disorders

Based on the Technology, the market is segmented into the following:
• Plasma-derived
• Recombinant

Based on the Distribution Channel, the market is segmented into the following:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on geography, the market is segmented into the following:

• North America
o USA
o Canada
• Europe
o Germany
o UK
o France
o Spain
o Italy
o Russia
o Rest of Europe
• The Asia Pacific
o China
o India
o Japan
o ASEAN
o Australia & New Zealand
o Rest of Asia-Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• MEA
o Gulf Cooperation Council (GCC) Countries
o Israel
o South Africa
o Rest of MEA

Request methodology at: https://precisionbusinessinsights.com/request-methodology/?product_id=65324

Key players in the Blood Clotting Factors Market report are AngioDynamics, Terumo Co., Johnson and Johnson, ECKOS Co., Bayer HealthCare LLC, Boston Scientific Co., Argon Medical Devices, Medtronic Plc, Teleflex Incorporated

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.